Jul. 30 at 6:17 AM
$CYCN This evening's FDA announcement presents a golden opportunity for Cyclerion to strategically release positive developments. A primary critique of CYCN is their apparent reluctance or inability to effectively engage with all shareholders and, more crucially, to sell themselves to Wall Street and all investors. Whoever approved their current communication strategy has miscalculated—it’s clearly ineffective. The leadership’s failure to grasp the importance of strategic marketing and persuasive communication is evident. The stock price, languishing at
$2.73 per share, speaks volumes. Dismiss my perspective if you will, but the numbers don’t lie. Furthermore, the much-touted hiring of an investor relations professional is a hollow gesture unless paired with action. What drives momentum is a compelling narrative of hope, ambition, and a clear vision for the future. Cyclerion must break free from its past constraints and act decisively—now is the time for a transformative announcement.
